Skip to content

Author

Qiu-Juan Wang

We have 1 of 3 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Dapagliflozin attenuates cardiomyocyte hypertrophy by inhibiting KEAP1-NRF2-mediated ferroptosis pathway.

OBJECTIVES Myocardial hypertrophy is a common pathological process in various cardiovascular diseases and may ultimately lead to heart failure. As a sodium-glucose cotransporter 2 inhibitor, dapagliflozin (DAPA) has been demonstrated to be cardioprotective, in addition to its hypoglycemic effect. However, the precise m...

Li-Ying Liang, Qiu-Juan Wang, H. Zhen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.